Navigation Links
Selexis to Exhibit at BIO Taiwan 2013
Date:7/16/2013

Geneva, Switzerland (PRWEB) July 16, 2013

Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today that representatives from the Company will be participating in the BIO Taiwan 2013 conference being held July 18 - 21, 2013 at Taipei Word Trade Center – Nangang Exhibition Hall in Nangang, Taipei, Taiwan.

Selexis has partnerships and commercial deals with leading biotechnology and pharmaceutical companies worldwide. The Selexis SUREtechnology Platform™ offers a range of solutions for recombinant protein expression and protein therapeutic development, including technologies and expression libraries for overcoming a wide range of secretion bottlenecks, screening platforms to facilitate lead identification of clinical candidates and development of high producing clonal cell lines for therapeutic protein programs. Selexis’ SUREtechnology Platform™ can be applied from early drug discovery to cGMP manufacturing, resulting in faster, more reliable, higher-expressing mammalian cell lines that can be applied to a wide range of areas such as diagnostics, drug discovery, therapeutics and bio-manufacturing.

Representatives will be available to discuss Selexis’ capabilities. Companies or individuals attending BIO Taiwan 2013 can meet with Selexis representatives at the BioAlps Lake Geneva Life Science Cluster booth number I216-218.
For more information, please visit http://www.bioclub.com.tw/en/vis_info.asp

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis generated cell lines are being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

Read the full story at http://www.prweb.com/releases/selexis_bio_taiwan/cell_line_development/prweb10927923.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Selexis SA to Present at Biotech Showcase 2012
2. Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
3. Data on the Selexis SUREtechnology Platform to be Presented at PEPTALK 2013
4. Selexis SA to Present at Cell Line Development and Engineering 2013
5. Selexis SA to Speak on Next Generation Innovations for Secretion Bottlenecks at the 2013 Protein Engineering Summit (PEGS)
6. At RSNA, DR Systems Will Exhibit RIS, Reporting, Peer Review Systems
7. 2011 ErgoExpo Attendees Choice Award Winners Announced During Sold Out Expo; Exhibitor Renewal for 2012 Hits 96% and Counting
8. FirstMark to Exhibit at Cardiovascular Research Technologies (CRT) 2012 Conference
9. FirstMark Exhibiting at the American College of Cardiology 61st Annual Scientific Sessions & Expo
10. NanoLogix Announces Development of Multi-Well, Rapid Diagnostic Test Variant and Exhibits at the American Society for Microbiology General Meeting in San Francisco
11. The Human Genome Is Displayed in the Dimension of Time in Web-Based Exhibition by Yonder Biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... to bring innovative medical technologies, services and solutions to the healthcare market. The ... implementation of various distribution, manufacturing, sales and marketing strategies that are necessary to ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):